Despite headlines suggesting a ban, the FDA has simply placed BPC-157 in a category requiring further investigation
Valente, A., Iribarren, D
Systemic Inflammation and Post-Injury Recovery For patients with widespread musculoskeletal inflammation, chronic soft tissue pain, or a recent surgical recovery, BPC-157 is most often prescribed as part of the Wolverine Stack, which combines BPC-157 with TB-500 (Thymosin Beta-4) for synergistic tissue repair
Zero hormonal side effects
Combined in one oral formulation, these compounds offer a versatile platform for examining cellular recovery, metabolic support, and structural integrity in various systems
Acknowledgments This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract HHSN261201500003I